Amneal Pharmaceuticals, Inc. (AMRX) |
|
1.29 -0.04 (-3.01%)
|
03-27 16:00 |
|
Open: |
1.34 |
Pre. Close: |
1.33 |
|
High:
|
1.35 |
Low:
|
1.26 |
|
Volume:
|
1,162,204 |
Market Cap:
|
392(M) |
|
|
|
Technical analysis |
as of: 2023-03-27 4:17:18 PM |
|
Overall:
|
 |
| Stoxline posted a NEUTRAL today, same as yesterday. Current trend continues, but could change at anytime. It is not a good time to buy or sell. |
| Target: |
Six months: 2.31  One year: 2.83 |
| Support: |
Support1: 1.25 Support2: 1.04 |
| Resistance: |
Resistance1: 1.98 Resistance2: 2.43 |
| Pivot: |
1.46 |
| Moving Average: |
MA(5): 1.37 MA(20): 1.59
MA(100): 2.14 MA(250): 2.69 |
| MACD: |
MACD(12,26): -0.3  Signal(9): -0.3 |
| Stochastic oscillator: |
%K(14,3): 4.8 %D(3): 8.3 |
| RSI: |
RSI(14): 26.8 |
| 52-week: |
High: 4.59 Low: 1.25 |
| Average Vol(K): |
3-Month: 1,114 (K) 10-Days: 1,136 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ AMRX ] has closed above bottom band by 18.7%. Bollinger Bands are 4% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
1.34 - 1.35 |
1.35 - 1.36 |
|
Low:
|
1.26 - 1.27 |
1.27 - 1.28 |
|
Close:
|
1.32 - 1.33 |
1.33 - 1.34 |
|
Company Description |
|
Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment develops, manufactures, and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals across a range of therapeutic categories. The Specialty segment is involved in the development, promotion, distribution, and sale of branded pharmaceutical products with focus on central nervous system disorders, endocrinology, parasitic infections, and other therapeutic areas. It also offers Emverm, a chewable tablet for the treatment of pinworm, whipworm, common roundworm, common hookworm, and American hookworm in single or mixed infections; Rytary to treat Parkinson's disease; and Unithroid for the treatment of hypothyroidism. The AvKARE segment provides pharmaceuticals, medical and surgical products, and services primarily to governmental agencies, the Department of Defense, and the Department of Veterans Affairs. It is also involved in the wholesale distribution of bottle and unit dose pharmaceuticals under the AvKARE and AvPAK names, as well as medical and surgical products; and packaging and wholesale distribution of pharmaceuticals and vitamins to its retail and institutional customers. The company sells its products through wholesalers, distributors, hospitals, chain pharmacies, and individual pharmacies. It operates in the United States, India, Ireland, and internationally. The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey. |
Headline News |
Sat, 11 Mar 2023
Amneal Pharmaceuticals (NYSE:AMRX) Price Target Cut to $4.00 - MarketBeat
Mon, 06 Mar 2023
Where Will Amneal Pharmaceuticals Inc (AMRX) Stock Go Next After It Has Fallen 11.57% in a Week? - InvestorsObserver
Mon, 06 Mar 2023
Amneal Pharmaceuticals, Inc. (NYSE:AMRX) Q4 2022 Earnings Call Transcript - Yahoo Finance
Sun, 05 Mar 2023
Amneal Pharmaceuticals (NYSE:AMRX) PT Lowered to $3.00 at The ... - MarketBeat
Thu, 02 Mar 2023
Amneal Pharmaceuticals Inc Down 7.67% To $1.95 After Earnings Beat - InvestorsObserver
Thu, 02 Mar 2023
Amneal Pharmaceuticals (AMRX) Beats Q4 Earnings and Revenue ... - Nasdaq
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Neutral |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Neutral |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NYSE |
| Sector: Healthcare |
| Industry: Drug Manufacturers—Specialty & Generic |
| Shares Out. |
152 (M) |
| Shares Float |
101 (M) |
|
% Held by Insiders
|
10.8 (%) |
|
% Held by Institutions
|
67.7 (%) |
|
Shares Short
|
7,120 (K) |
|
Shares Short P.Month
|
9,110 (K) |
Stock Financials |
|
EPS
|
-0.84 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
1.97 |
|
Profit Margin (%)
|
-5.9 |
|
Operating Margin (%)
|
9 |
|
Return on Assets (ttm)
|
3.2 |
|
Return on Equity (ttm)
|
-86 |
|
Qtrly Rev. Growth
|
13.6 |
|
Gross Profit (p.s.)
|
5.22 |
|
Sales Per Share
|
14.58 |
|
EBITDA (p.s.)
|
2.9 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
65 (M) |
|
Levered Free Cash Flow
|
120 (M) |
Stock Valuations |
|
PE Ratio
|
-1.54 |
|
PEG Ratio
|
-0.3 |
|
Price to Book value
|
0.65 |
|
Price to Sales
|
0.08 |
|
Price to Cash Flow
|
3 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
